Nutra Pharma is announcing its agreement with an Internet marketing firm for their Over-the-Counter Pain Remedies: Nyloxin® and Pet Pain-Away™
CORAL SPRINGS, Fla., July 17, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Nutra Pharma Corporation (OTC:NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, announced today that it has executed an agreement with American Marketing Technologies (“AMT”) to launch an integrated Internet marketing campaign combined with a program to target a number of national retail chains.
“According to a 2016 article published in the Washington Post, over 35 percent of adults in the United States have been on prescription pain killers; which is around 85 million people,” commented Rik J Deitsch, CEO of Nutra Pharma Corporation. “With more than 80 percent of Americans currently shopping online, it’s clear that we need the expertise of AMT to educate and market our products to the people that need them most,” he continued. “We have already begun working with this firm and are seeing great progress and we roll out our message: these are powerful, non-narcotic pain relievers that address the opioid crisis in a safe and sustainable way,” he concluded.
Nutra Pharma re-launched their product websites recently, but had not yet defined their plans for marketing and growth of their OTC product lines. The Company also recently announced the infomercial campaigns specifically promoting Pet Pain-Away™.
“AMT’s approach to market these exceptional pain-relief products is to create more awareness through social media and online marketing while trying to have these products available on shelves across the country,” stated Pablo Lavigna, AMT’s Chief Technology Officer. “Our team will provide Nutra Pharma with the ability to reach their vast audience of potential users through SEO and more traditional distribution channels in a staged and consistent manner. As we build brand awareness online; it will provide the pull-through to put these amazing products on store shelves throughout the US,” he concluded.
Nyloxin® is a safe, non-narcotic, and non-addictive Homeopathic pain reliever clinically proven to treat moderate to severe chronic pain while not impairing cognitive function. Nyloxin® offers several benefits as pain relievers and anti-inflammatory agents. With increasing concern about consumers using opioid and acetaminophen-based pain relievers, Nyloxin® offers an opioid-free alternative that does not rely on opiates or non-steroidal anti-inflammatory drugs, otherwise known as NSAIDs, for their pain relieving effects. Nyloxin® has a well-defined safety profile. Since the early 1930s, the active pharmaceutical ingredient (API), Asian cobra venom, has been studied in more than 46 human clinical studies.
Pet Pain-Away™ is a homeopathic, non-narcotic, non-addictive, over-the-counter pain reliever. The product is primarily aimed at treating moderate to severe chronic pain in companion animals. It is specifically indicated to treat pain from hip dysplasia, arthritis pain, joint pain, and general chronic pain in dogs and cats. Specialized proteins in Pet Pain-Away™ block the action of acetylcholine, a major stimulating neurotransmitter in the nervous system and activator of the inflammatory pathways. As a result, the pain and inflammation pathways are temporarily shut off.
About American Marketing Technologies, LLC
American Marketing Technologies is a digital marketing company that specializes in maximizing online presence. From branding and website design to Search Engine Optimization (SEO), its team provides the resources to make businesses more successful in today’s competitive digital economy. The best product or service will never reach the thousands of potential customers who are searching the Internet daily if it is not effectively marketed online. Its mission is to ensure clients achieve top search engine rankings and to convert clicks into customers.
For additional information on American Marketing Technologies, visit:
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away™. For additional information about Nutra Pharma, visit:
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The agreement with AMT should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
Nutra Pharma Corp.